inhibitor | Acetylcholinesterase inhibitor | Selective serotonin reuptake inhibitor | Enzyme inhibitor | enzyme inhibitor | Metalloprotease inhibitor | Matrix metalloproteinase inhibitor | Inhibitor | Farnesyltransferase inhibitor | COX-2 inhibitor | ALK inhibitor | ACE inhibitor |
In the 1970s, WFEB scientists undertook the first systematic study of anti-tumor effects of the anti-estrogen tamoxifen led by 2003 Kettering Prize recipient V. Craig Jordan and initial studies of aromatase inhibitors by 2005 Kettering prize recipient Angela Brodie, two important classes of drugs to treat breast cancer.